https://doi.org/10.55788/ad496416
The phase 3 NAPOLI-3 trial showed that liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) outperformed nab-paclitaxel plus gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma (mPDAC).
The phase 3 NAPOLI-3 trial (NCT04083235) compared nab-paclitaxel plus gemcitabine with NALIRIFOX for the first-line treatment of 770 patients with mPDAC [1]. Eligible patients were randomised 1:1 to evaluate the primary endpoint of overall survival (OS). Prof. Zev Wainberg (University of California Los Angeles, CA, USA) presented the late-breaking results.
After a median follow-up of 16.1 months, the OS was significantly improved in the NALIRIFOX arm compared with the control arm (median OS 11.1 months vs 9.2 months; HR 0.83; 95% CI 10.0–12.1; P=0.04, see Figure). Prof. Wainberg added that the OS curves started to separate from 3 months and remained separated through the further course of the study. Similarly, progression-free survival (PFS) was improved in patients receiving NALIRIFOX arm compared with those receiving nab-paclitaxel plus gemcitabine (median PFS 7.4 months vs 5.6 months; HR 0.69; 95% CI 0.58–0.83; P<0.0001). Additionally, all subgroups showed to have a benefit.
Figure: Overall survival of NALIRIFOX versus nab-paclitaxel plus gemcitabine [1]
NALIRIFOX, liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin; Gem, gemcitabine; NabP, nab-paclitaxel.
Prof. Wainberg mentioned that NALIRIFOX had a manageable safety profile, consistent with the toxicity profiles of the individual treatment components. Comparable rates of grade 3 or higher adverse events (AEs) were reported for the 2 study groups (87.0% and 86.0%). However, grade 3 or 4 haematologic AEs were more common among patients receiving nab-paclitaxel plus gemcitabine, whereas those who were exposed to NALIRIFOX showed higher rates of grade 3 or 4 diarrhoea (20.3% vs 4.5%), nausea (11.9% vs 2.6%), and vomiting (7.0% vs 2.1%).
Prof. Wainberg concluded that these results support the administration of NALIRIFOX as first-line therapy for patients with mPDAC. Of note, NALIRIFOX is a new standard-of-care for fit patient if liposomal irinotecan is available in the first line.
- Wainberg ZA, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Late-breaking abstract 661, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Novel approach delivers quality-of-life benefits for patients with pancreatic cancer Next Article
Letter from the Editor »
Table of Contents: ASCO GI 2023
Featured articles
Oesophageal and Gastric Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Anal and Colorectal Cancer
IMbrave 151 missed primary endpoint in advanced BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Hepatobiliary Cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Pancreatic Cancer
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy